미국 · 보도자료 · Sagimet Biosciences Inc. · 2026-10-09 11:00
새기멧, 여드름 치료제 데니판스타트 3상 52주 긍정적 임상 결과 발표
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the positive 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd
Sagimet Biosciences Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
